Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar (Mohali), Punjab, India.
Crit Rev Ther Drug Carrier Syst. 2011;28(1):1-45. doi: 10.1615/critrevtherdrugcarriersyst.v28.i1.10.
Nanocarriers formulated with the US Food and Drug Administration-approved biocompatible and biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) are being widely explored for the controlled delivery of therapeutic drugs, proteins, peptides, oligonucleotides, and genes. Surface functionalization of PLGA nanoparticles has paved the way to a variety of engineered PLGA-based nanocarriers, which, depending on reticular requirements, can demonstrate a wide variety of combined properties and functions such as prolonged residence time in blood circulation, enhanced oral bioavailability, site-specific drug delivery, and tailored release characteristics. The present review highlights the recent leaps in PLGA-based nanotechnology with a particular focus on cancer therapeutics. Starting with a brief introduction to cancer nanotechnology, we then discuss developmental aspects and the in vitro and in vivo efficacy of PLGA-based nanocarriers in terms of targeted drug or gene delivery. The main objective of this review is to convey information about the state of art and to critically address the limitations and the need for further progress and clinical developments in this emerging technology.
载药纳米载体通常由美国食品和药物管理局批准的生物相容性和可生物降解聚合物聚乳酸-共-羟基乙酸（PLGA）制成，目前正被广泛探索用于治疗药物、蛋白质、多肽、寡核苷酸和基因的控制释放。PLGA 纳米颗粒的表面功能化开辟了各种工程化的基于 PLGA 的纳米载体的道路，这些纳米载体根据网状要求，可以展示出多种组合性质和功能，例如在血液循环中的延长停留时间、增强口服生物利用度、靶向药物递送和定制释放特性。本综述重点介绍了基于 PLGA 的纳米技术的最新进展，特别是癌症治疗方面的进展。从简要介绍癌症纳米技术开始，然后我们讨论了基于 PLGA 的纳米载体在靶向药物或基因传递方面的体外和体内功效的发展方面。本综述的主要目的是传达有关该领域的最新信息，并批判性地解决该新兴技术的局限性以及进一步发展和临床应用的需求。
